Several randomized controlled trials that were reported at the conference in the current year showed that neoadjuvant immunotherapy achieved significant efficacy in early resectable NSCLC, with a low incidence of treatment-related adverse events. For early resectable NSCLC, single-arm trials and meta-analyses previously reported that patients exhibited good pathological responses following neoadjuvant immunotherapy. Importantly, such incidences of adverse reactions are much lower than those reported in the case of chemotherapy. In fact, the incidence of treatment-related adverse reactions remains high. However, there are cases where patients did not benefit significantly. In general, immunotherapy has prolonged the survival of patients with advanced NSCLC. In fact, more and more clinical studies are being conducted to assess the efficacy of immunotherapy in NSCLC in a detailed manner. Previous clinical studies confirmed the efficacy of immunotherapy in advanced NSCLC. Ĭurrently, immunotherapy is widely used for the treatment of various stages of NSCLC. Importantly, these benefits were observed when it was used alone with PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, or in combination with chemotherapy, antivascular drugs, or even in the case of dual immunotherapy agents. Previous clinical studies on immunotherapy showed that immunotherapy incurred better clinical benefits than previously used chemotherapeutic strategies. Following this, immunotherapy emerged as a promising approach. In the case of patients with driver gene negative profiles, only chemotherapy has been used for a long time. Importantly, targeted therapy prolonged the survival in such patients. The emergence of targeted therapy enabled the treatment of patients with NSCLC tested positive for driver gene. A large number of studies are being conducted to explore therapeutic strategies for NSCLC. Importantly, 80% of the newly discovered lung cancers are contributed by non-small cell lung cancer (NSCLC). In fact, it is the most common cause of cancer-related deaths. Lung cancer is still among the most common cancer types reported worldwide. In terms of safety, both immunotherapy alone and its combination with chemotherapy were found to be safer in early lung cancer as compared to advanced lung cancer. ConclusionsĪltogether, the benefits of immunotherapy in early lung cancer appeared to be better than those observed in advanced lung cancer, especially with the regard to the regimen of immunotherapy in combination with chemotherapy. In terms of safety, immunotherapy either alone or in combination with other therapies exhibited a better safety profile in early lung cancer than in advanced lung cancer. The combination of immunotherapy with other therapies, especially immunochemotherapy, significantly improved ORR and DCR in early lung cancer. Importantly, the improvement in ORR was not to the same extent as reported in the case of advanced lung cancer. It was observed that immunotherapy alone significantly improved DCR in early lung cancer in comparison to advanced lung cancer. ResultsĪ total of 52 randomized controlled trials involving 13,660 patients were shortlisted. ORR, DCR, and TRAEs were extracted as the primary outcomes. Besides this, all the available reviews, abstracts, and meeting reports from the main international lung cancer meetings were searched manually. MethodsĮlectronica databases, including PubMed, Cochrane Library, Embase, and other databases, were searched to identify relevant studies. The present study also evaluated the safety of immunotherapy in early and late lung cancer, wherein the rate of treatment-related adverse reactions (TRAEs) was used as an indicator. This systematic review aimed to evaluate the efficacy of immunotherapy in early and late lung cancer, wherein objective response rate (ORR) and disease control rate (DCR) were used as evaluation indexes. However, this observation has not been established in clinical studies. According to clinical experience and results of previous studies, immunotherapy as neoadjuvant therapy seems to exhibit better efficacy against early resectable non-small cell lung cancer as compared to advanced lung cancer, which is often defined as unresectable non-small cell lung cancer. Currently, immunotherapy is widely used in the treatment of various stages of non-small cell lung cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |